TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00538954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Post operative laxation (Magnesium Oxide)
Description: 20 ml of Magnesium Oxide twice daily from the day after surgery until discharge

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Post operative laxation (Magnesium Oxide)
Description: 20 ml of Magnesium Oxide twice daily from the day after surgery until discharge

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Preoperative metabolic conditioning postoperative nutritional supplementation
Description: Nutricia PreOP drinks 800 ml between 8-10 pm the evening before surgery Nutricia PreOP drinks 400 ml completed 2 hours before anaesthesia on the morning of surgery Nutricia Fortisip drinks 2 x 200 ml drinks from the day after surgery until day 30

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Preoperative metabolic conditioning postoperative nutritional supplementation
Description: Nutricia PreOP drinks 800 ml between 8-10 pm the evening before surgery Nutricia PreOP drinks 400 ml completed 2 hours before anaesthesia on the morning of surgery Nutricia Fortisip drinks 2 x 200 ml drinks from the day after surgery until day 30

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard ERAS group
Study: NCT03666806

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Influenza vaccine
Description: The randomized FLUVACS trial demonstrated the benefits of influenza vaccination in the prevention of cardiovascular death. In the VIPS study the risk for acute ischaemic stroke (AIS) in children increased by 6-fold compared to the baseline population. It was postulated that infections and in particular upper respiratory tract infections acts as a stroke trigger in a child who is otherwise predisposed to stroke and why it would occur at a particular point in that child's life. It should be noted that major infections such as meningitis have been causes of stroke while this study has shown that minir infections can also act as a trigger for stroke in adults
Study: NCT02690597

Intervention type: OTHER
Group type: OTHER
Intervention: Anxiety visual analog scale
Description: Anxiety visual analog scale is a test of evaluation of anxiety done by the patient, this scale do not include number and the patient have to place a coloured marker at the level indicating his anxiety feeling
Study: NCT01000181

Intervention type: OTHER
Intervention: PET-CT with CuATSM
Description: PET-CT with CuATSM
Study: NCT01189708

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrapro® Mesh implantation
Description: After the aortic procedure (aortic aneurysm repair) an Ultrapro absorbable mesh will be used for the wound closure of the abdominal wall using an onlay technique.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard wound closure
Description: Abdominal closure will be performed with standard sutures without a mesh.
Study: NCT04591457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine Sansulin
Description: Insulin Glargine (Sansulin Log-G) once daily at individually adjusted dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine Pen Injector [Lantus]
Description: Insulin Glargine (Lantus) once daily at individually adjusted dose
Study: NCT01870167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: co-amoxiclav
Description: a single iv dose of co-amoxiclav (50/mg/Kg) at the time of PEG insertion.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00723463

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3T MRI scan
Description: Establishing/evaluating apparent diffusion coefficient (ADC) values using a 3T MRI scan to differentiate tumors from normal tissue.
Study: NCT05054686

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stretching and Aerobic Exercise at Clinic
Description: In this group of knee osteoarthritis patients will be applied both stretching and 30 minutes bicycle exercises in the same session, strengthening exercises and 30 minutes walking will be given in seperate days as home program.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Strenghthening and Aerobic Exercise
Description: In this group of knee osteoarthritis patients will be applied both strengthening and 30 minutes bicycle exercises in the same session, 2 days strecthing exercises and 30 minutes walking will be given in seperate days as home program.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Strengthening, Stretching and Aerobic Exercises at clinic
Description: In this group of knee osteoarthritis patients will be applied all stretching, strengthening and 30 minutes bicycle exercises in the same session, only 30 minutes walking will be given as home program.
Study: NCT00978393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: High dose liraglutide treatment (3.0 mg) followed by low dose liraglutide treatment (1.8 mg). Injected s.c. (under the skin) once daily in the evening.
Study: NCT02394665

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiation Therapy
Description: IMRT treatment will consist of 60 Gy in 30 fractions to PTV 60

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiation Therapy
Description: IMRT treatment will consist of 60 Gy in 30 fractions to PTV 60
Study: NCT00978393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Low dose liraglutide treatment (1.8 mg) followed by high dose liraglutide treatment (3.0 mg). Injected s.c. (under the skin) once daily in the evening.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Low dose liraglutide treatment (1.8 mg) followed by high placebo treatment (3.0 mg). Injected s.c. (under the skin) once daily in the evening.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: High placebo treatment (3.0 mg) followed by low dose liraglutide treatment (1.8 mg). Injected s.c. (under the skin) once daily in the evening.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: High dose liraglutide treatment (3.0) followed by low placebo treatment (1.8 mg). Injected s.c. (under the skin) once daily in the evening.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Low placebo treatment (1.8 mg) followed by high dose liraglutide treatment (3.0 mg). Injected s.c. (under the skin) once daily in the evening.
Study: NCT03763058

Intervention type: OTHER
Group type: OTHER
Intervention: Music Therapy
Description: The music intervention is administered via a smartphone- (and computer-) based application called Music Care. The Music Care app is a receptive music intervention, allowing the patient to freely adjust the length of and choose the preferred style between different sequences of instrumental music. All musical pieces were recorded in high-quality recording studios with professional musicians. Music Care utilizes the U technique designed to gradually relax the listener. The U technique is implemented using a musical sequence of 20 minutes that was divided into 5 different musical pieces at 3 to 4 minutes each.~Participants will complete 1-2 sessions of listening to music per day, with a minimum of 15 sessions per month.
Study: NCT01593254

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imatinib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dasatinib
Study: NCT02295267

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: walnut allergy provocation
Description: double blind placebo controlled food challenge
Study: NCT01230216

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: control systolic blood pressure less than 120 mmHg
Description: use losartan to control blood pressure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: control systolic blood pressure less than 140 mmHg
Description: use losartan to control blood pressure
Study: NCT01745107

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Prophylactic postoperative radiation therapy
Description: Prescription dose of 95%planning target volume(PTV) 50.4Gy/1.8Gy/28fractions for supraclavicular region and 95%PTV 56Gy/2Gy/28fractions for mediastinum which is delivered in 2 months after surgery.
Study: NCT03544125

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO
Study: NCT01652625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yunnan Baiyao toothpaste
Description: The patients were instructed to brush the teeth twice daily for 5 days, using 1 gram of Yunnan Baiyao toothpaste (equivocal to approximately 6-7 lines on a standard toothbrush) for 3 minutes. 6.5 milligrams of Yunnan Baiyao active extract were contained in 1 gram of the toothpaste.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo toothpaste
Description: One gram of the placebo toothpaste was used twice daily by the control group patients. Except for the active Yunnan Baiyao extract, all ingredients contained in the placebo-toothpaste were the same as that in the experimental toothpaste.
Study: NCT04273867

Intervention type: OTHER
Intervention: Chronic Hypersensitivity Pneumonitis Health Related Quality of Life Survey Instrument
Description: This survey has been developed and revised from prior qualitative research with CHP patients and will be used to better evaluate disease status and quality of life with CHP.
Study: NCT00179894

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physician training
Description: Physicians are trained in guidelines for medication management.
Study: NCT04629872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fingolimod
Description: Patients randomized to fingolimod will also receive oral fingolimod (Gilenya, Novartis) at a dosage of 0.5 mg once daily, for three consecutive days, with the first dose being given at the time in which patients are enrolled which is more than 3 hour prior to mechanical thrombectomy.
Study: NCT02131636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-199201
Description: AGN-199201 applied to the face once daily for 29 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle to AGN-199201
Description: Vehicle to AGN-199201 applied to the face once daily for 29 days.
Study: NCT00609713

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive behavioral weight control program
Description: Participants will meet weekly for 12 weeks, then every other week for 12 weeks, and once a month thereafter through week 52. Adolescents and parents will receive manuals that provide lessons and homework assignments for each meeting. The program for the first 22 weeks includes the following topics: 1) the causes of obesity; 2) components of healthy nutrition; 3) self-monitoring of calories, physical activity, and inactivity; 4) stimulus control procedures; 5) coping with high-risk social or psychological situations that trigger excess eating; 6) increasing physical activity; and 7) minimizing inactivity. At each session, participants will submit their self-monitoring diaries and completed homework. Incentives for completion of self-monitoring tasks are an integral part of the behavior modification program and a small gift certificate will be given to subjects for successful completion at each intervention session.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Individual 12-month nutrition education program
Description: The other half of the participants (44 subjects) will be randomized to this arm of the intervention (usual care), which will also start in five waves. In contrast to the comprehensive behavioral weight control program, the nutrition education program will take place through individual appointments with a clinical dietician to reflect usual care and mimic the present approach used for the treatment of obese adolescents at the Children's Hospital of Philadelphia (CHOP) Nutrition Consultation. Parents will be required to take part in the consultations. The first consultation will last 60 minutes and the following consultations of 30 minutes will take place once a month for the first six months, then every other month for the second six months, as is the usual practice in our clinical setting.
Study: NCT01980498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl pectin nasal spray (FPNS)
Description: The first dose of FPNS will be 100 mcg dose. It will be increased until 800 mcg dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Physician choice-Usual care (PC-UC)
Description: The PC-UC will be started at a dose according to the physician choice. If this dose of PC-UC is effective on pain control, at the following meal the patient will take the same dose of PC-UC.~If the dose of PC-UC results non effective on pain control, at the following meal the patient will take an increased dose of the same PC-UC drug or change the PC-UC drug, according to the physician choice.
Study: NCT00776620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride 1mg Tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride 1mg Tablets
Study: NCT02350699

Intervention type: DEVICE
Intervention: Nautilus BrainPulse
Description: A noninvasive device to detect concussion utilizing headset and sensors
Study: NCT02445859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefuroxime 4 hourly bolus
Description: Cefuroxime loading dose followed by a continuous infusion dosed according to renal function. Dosed to target a serum concentration of 64mg/L.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefuroxime 4 hourly bolus
Description: Cefuroxime loading dose followed by a continuous infusion dosed according to renal function. Dosed to target a serum concentration of 64mg/L.
Study: NCT04110496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTX-134
Description: RTX-134 is a cellular therapy containing AvPAL
Study: NCT00346567

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zidovudine and Lamivudine (Combivir)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine and Tenofovir (Truvada)
Study: NCT03749421

Intervention type: OTHER
Intervention: Prosigna PAM-50 assay
Description: Looks at the gene activity of a person's cancer cells to determine the likely outcome or course of a disease (prognosis) and predict the benefit of chemotherapy or endocrine therapy after breast surgery
Study: NCT04282837

Intervention type: DIAGNOSTIC_TEST
Intervention: AI classification of patients with obesity
Description: Computational modeling techniques will be used for the precise reclassification of obesity into four subgroups, several variables according to the clinical experience and the modeling results will be selected for the cluster analysis.

Intervention type: DIAGNOSTIC_TEST
Intervention: AI classification of patients with obesity
Description: Computational modeling techniques will be used for the precise reclassification of obesity into four subgroups, several variables according to the clinical experience and the modeling results will be selected for the cluster analysis.

Intervention type: DIAGNOSTIC_TEST
Intervention: AI classification of patients with obesity
Description: Computational modeling techniques will be used for the precise reclassification of obesity into four subgroups, several variables according to the clinical experience and the modeling results will be selected for the cluster analysis.

Intervention type: DIAGNOSTIC_TEST
Intervention: AI classification of patients with obesity
Description: Computational modeling techniques will be used for the precise reclassification of obesity into four subgroups, several variables according to the clinical experience and the modeling results will be selected for the cluster analysis.
Study: NCT04491526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAMSULOSIN Mepha Ret Depocaps 0.4 mg
Description: 0.4mg/day Tamsulosin hydrochloride (TAMSULOSIN Mepha Ret Depocaps 0.4 mg) from 5 days prior to the day of surgery, at the day of surgery and for 1 day following surgery. (5+1+1)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control Intervention
Description: One placebo capsule matching the active study drug per day from 5 days prior to the day of surgery, at the day of surgery and for 1 day following surgery. (5+1+1)
Study: NCT00650286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil Tablets 200 mg
Description: 200mg, single dose fed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Provigil® Tablets 200 mg
Description: 200mg, single dose fed
Study: NCT01449513

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ingenol mebutate
Description: 0.05% Ingenol mebutate Gel once daily for 2 consecutive days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Gel
Description: Gel vehicle of PEP005
Study: NCT02039323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Study: NCT03891823

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MitraClip
Description: Study participants will be randomized to MitraClip device to determine treatment efficacy in improving LV remodelling or functional capacity.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MitraClip
Description: Study participants will be randomized to MitraClip device to determine treatment efficacy in improving LV remodelling or functional capacity.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medical Therapy
Description: Study participants will be randomized to medical therapy to determine treatment efficacy in improving LV remodelling or functional capacity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medical Therapy
Description: Study participants will be randomized to medical therapy to determine treatment efficacy in improving LV remodelling or functional capacity.
Study: NCT04102683

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic recreation activity program
Description: The experimental recreation program, which consisted of two sessions per week and lasted approximately 1 hour each session, lasted for 8 weeks between March 2019 and May 2019 for the adolescents in the experimental group. The Therapeutic Recreation Activity Program, which consists of 16 sessions, is organized according to the self-determination and entertainment development model. This model aims to provide individual development and prosperity by creating an entertaining environment with therapeutic recreation. According to the degree of enjoyment, activity improves freedom of choice, preferences and ability to express oneself. Pleasure is a feeling that the participant feels deeply during therapeutic recreation. Provides entertainment experience. Pleasure increases individual motivation to participate, as well as making the best use of physical, social and emotional conditions.
Study: NCT01180023

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sweeping
Description: Sweeping of membranes during digital exam
Study: NCT01732445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ruxolitinib phosphate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: danazol
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study: NCT01004432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golimumab 50 mg SC
Description: Golimumab 50 milligram (mg) subcutaneous (SC) injection every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golimumab 50 mg SC
Description: Golimumab 50 milligram (mg) subcutaneous (SC) injection every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golimumab 50 mg SC
Description: Golimumab 50 milligram (mg) subcutaneous (SC) injection every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golimumab 50 mg SC
Description: Golimumab 50 milligram (mg) subcutaneous (SC) injection every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golimumab 2 mg/kg IV
Description: Golimumab 2 milligram per kilogram (mg/kg) intravenous infusion every 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Description: Participants will continue taking their current Methotrexate (MTX) treatment regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Description: Participants will continue taking their current Methotrexate (MTX) treatment regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Description: Participants will continue taking their current Methotrexate (MTX) treatment regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Description: Participants will continue taking their current Methotrexate (MTX) treatment regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Description: Participants will continue taking their current Methotrexate (MTX) treatment regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo SC
Description: Placebo matched to golimumab SC injection every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo IV
Description: Placebo matched to golimumab intravenous infusion every 8 weeks.